U.S. markets closed
  • S&P 500

    4,326.51
    -23.42 (-0.54%)
     
  • Dow 30

    34,160.78
    -7.31 (-0.02%)
     
  • Nasdaq

    13,352.78
    -189.34 (-1.40%)
     
  • Russell 2000

    1,931.29
    -45.18 (-2.29%)
     
  • Crude Oil

    87.07
    -0.28 (-0.32%)
     
  • Gold

    1,794.80
    -34.90 (-1.91%)
     
  • Silver

    22.75
    -1.06 (-4.44%)
     
  • EUR/USD

    1.1146
    -0.0099 (-0.88%)
     
  • 10-Yr Bond

    1.8070
    -0.0410 (-2.22%)
     
  • GBP/USD

    1.3380
    -0.0082 (-0.61%)
     
  • USD/JPY

    115.3500
    +0.6900 (+0.60%)
     
  • BTC-USD

    35,751.45
    -1,183.05 (-3.20%)
     
  • CMC Crypto 200

    808.71
    -10.80 (-1.32%)
     
  • FTSE 100

    7,554.31
    +84.53 (+1.13%)
     
  • Nikkei 225

    26,170.30
    -841.03 (-3.11%)
     

Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?

·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • ROG.SW
  • BIIB

Roche (OTC: RHHBY) is considering a launch of its Alzheimer's disease drug, gantenerumab, at a price that could undercut competition from Biogen's (NASDAQ: BIIB) Aduhelm. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss reasons why Biogen investors should be concerned if Roche's drug gains FDA approval.